ARS Pharmaceuticals (SPRY) Non Operating Income (2022 - 2026)

ARS Pharmaceuticals has disclosed Non Operating Income across 5 years of filings, most recently posting -$473000.0 for Q1 2026.

• Non Operating Income for Q1 2026 came in at -$473000.0, down 114.61% year-over-year; the trailing twelve-month figure through Mar 2026 was $4.4 million (down 62.75% YoY), and the FY2025 annual result was $8.1 million, down 29.02% from the prior year.
• Non Operating Income came in at -$473000.0 for Q1 2026 at ARS Pharmaceuticals, down from $61000.0 in the prior quarter.
• In the past five years, Non Operating Income ranged from a high of $3.8 million in Q1 2023 to a low of -$473000.0 in Q1 2026.
• The 5-year median for Non Operating Income is $2.7 million (2025), against an average of $1.9 million.
• Across the five-year window, Non Operating Income soared 6521.28% in 2023 and slumped 114.61% in 2026, its largest moves.
• ARS Pharmaceuticals' Non Operating Income stood at $1.2 million in 2022, then surged by 164.99% to $3.1 million in 2023, then fell by 1.08% to $3.0 million in 2024, then sank by 97.98% to $61000.0 in 2025, then tumbled by 875.41% to -$473000.0 in 2026.
• The last three Non Operating Income figures came in at -$473000.0 (Q1 2026), $61000.0 (Q4 2025), and $2.0 million (Q3 2025), per Business Quant data.